Development of New Atomic-Based EPR Spin Probes

新型原子 EPR 自旋探针的开发

基本信息

  • 批准号:
    8253407
  • 负责人:
  • 金额:
    $ 14.91万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2012
  • 资助国家:
    美国
  • 起止时间:
    2012-09-01 至 2015-08-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Development of New Atomic-Based EPR Spin Probes Summary/Abstract The use of electron paramagnetic resonance (EPR) methods in medicine is a rapidly advancing field. There has been significant progress in the past decade, and EPR may soon be used to guide the treatment of cancer, strokes, and conditions where it is crucial to make non-invasive measurements of oxygenation and hypoxia. However, further improvements to increase its sensitivity to detect radicals generated by reactive oxygen species (ROS) would make it applicable to a wider range of diseases. A key component of the biomedical EPR system is the spin probe, the fundamental chemical agent necessary to detect paramagnetic radicals. However, current spin probes have limitations. For example, the current generation of spin probes are not sensitive enough to directly detect or image the in vivo generation of reactive oxygen species in age related disorders or diseases mediated by ROS such as Parkinson's and Alzheimer's disease. To overcome these limitations, we propose to investigate new spin probes based upon paramagnetic atoms encapsulated in fullerene cages. Atoms containing unpaired electrons, such as atomic nitrogen pinned at the center of the symmetric C60 cage, are completely protected from reaction with external species and produce unprecedented narrow line widths. For example, N@C60 has one of the narrowest known EPR line widths, giving it a detection efficiency 100 to 1000 times better than the current compounds. In addition to protecting the encapsulated atom, the fullerene cage can interact with radical species, and reactions occurring on the surface of N@C60 produce measurable shifts in its EPR spectrum. Such features, along with proven biological compatibility, make fullerene-encapsulated atoms ideal spin probes. N@C60 epitomizes the ideal spin probe, but research on it is currently hindered by difficulties in producing and purifying it in bulk. However, atomic N is not the only possible choice for fullerene encapsulation. We have examined alternative atoms that will have similar EPR properties, but will be far easier to produce commercially. The specific aim of this project is to synthesize and characterize the most promising of these candidates and demonstrate that it can form the basis for a new type of EPR spin probe with many advantages over the current compounds. PUBLIC HEALTH RELEVANCE: Electron paramagnetic resonance (EPR) is an emerging technique similar to magnetic resonance imaging (MRI) that has the potential to help diagnose and guide the treatment of diseases such as cancer, stroke, and other conditions involving disruption of reactive oxygen species (ROS) homeostasis. EPR relies upon molecular agents called spin probes to interact with nearby oxygen or reactive oxygen radicals to generate a detectable signal. However, new compounds with higher sensitivity are needed to improve EPR technology and allow it to be used for more diseases. To remove the limitations inherent to current spin probes, we propose to investigate new types of spin probes based upon paramagnetic atoms encapsulated in C60 fullerenes that will have higher sensitivity in their ability to detect reactive oxygen species. The development of new spin probes that allow in vivo detection of ROS produced, for example, by Parkinson's and other ROS diseases would represent a significant advance in biomedical EPR technology.
描述(申请人提供):新的基于原子的EPR自旋探针的发展概述/摘要电子顺磁共振(EPR)方法在医学上的应用是一个快速发展的领域。在过去的十年中已经取得了重大进展,EPR可能很快就会被用来指导癌症、中风和对氧合和缺氧进行非侵入性测量至关重要的疾病的治疗。然而,进一步改进以提高其对检测由活性氧物种(ROS)产生的自由基的灵敏度将使其适用于更广泛的疾病。生物医学EPR系统的一个关键组件是自旋探针,它是检测顺磁自由基所必需的基本化学试剂。然而,目前的自旋探测器存在局限性。例如,当前一代的自旋探针不够灵敏,不足以直接检测或成像年龄相关疾病或由ROS介导的疾病(如帕金森氏症和阿尔茨海默病)中体内活性氧物种的生成。为了克服这些限制,我们建议研究基于封装在富勒烯笼子中的顺磁原子的新的自旋探针。含有未配对电子的原子,例如钉在对称C60笼子中心的氮原子,完全受到保护,不与外部物种反应,产生前所未有的窄线宽。例如,N@C60具有已知的最窄的EPR线宽之一,使其检测效率比目前的化合物高100至1000倍。除了保护被包裹的原子外,富勒烯笼子还可以与自由基物种相互作用,而发生在N@C60表面的反应在其EPR谱中产生了可测量的位移。这些特征,加上已被证明的生物兼容性,使富勒烯包裹的原子成为理想的自旋探针。N@C60是理想的自旋探针的缩影,但目前对它的研究受到批量生产和提纯的困难的阻碍。然而,N原子并不是富勒烯封装的唯一可能的选择。我们已经研究了具有类似EPR性质的替代原子,但更容易商业生产。该项目的具体目标是合成和表征其中最有希望的候选化合物,并证明它可以形成一种新型的EPR自旋探针,与目前的化合物相比具有许多优势。 公共卫生相关性:电子顺磁共振(EPR)是一种类似于磁共振成像(MRI)的新兴技术,有可能帮助诊断和指导癌症、中风和其他涉及活性氧物种(ROS)动态平衡的疾病的治疗。EPR依靠称为自旋探针的分子试剂与附近的氧或活性氧自由基相互作用,产生可检测到的信号。然而,需要灵敏度更高的新化合物来改进EPR技术,使其能够用于更多的疾病。为了消除目前自旋探针固有的局限性,我们建议研究基于C60富勒烯中的顺磁原子的新型自旋探针,这种自旋探针在检测活性氧物种方面将具有更高的灵敏度。新的自旋探针的开发将代表着生物医学EPR技术的重大进步,该探针可以在体内检测例如帕金森氏症和其他ROS疾病产生的ROS。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

JOHN M ALFORD其他文献

JOHN M ALFORD的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('JOHN M ALFORD', 18)}}的其他基金

Lanthanide Radionuclide Production
稀土放射性核素生产
  • 批准号:
    7538452
  • 财政年份:
    2008
  • 资助金额:
    $ 14.91万
  • 项目类别:
Development of Improved Spin Probes for Aging Research
用于老化研究的改进自旋探针的开发
  • 批准号:
    7219781
  • 财政年份:
    2007
  • 资助金额:
    $ 14.91万
  • 项目类别:
OPTIMIZATION OF TIME-OF-FLIGHT MASS SPECTROSCOPY
飞行时间质谱的优化
  • 批准号:
    6143975
  • 财政年份:
    2000
  • 资助金额:
    $ 14.91万
  • 项目类别:
Development of Carboxyfullerene Drugs to Treat ALS
治疗 ALS 的羧基富勒烯药物的开发
  • 批准号:
    6550613
  • 财政年份:
    1998
  • 资助金额:
    $ 14.91万
  • 项目类别:
Development of Carboxyfullerene Drugs to Treat ALS
治疗 ALS 的羧基富勒烯药物的开发
  • 批准号:
    6666951
  • 财政年份:
    1998
  • 资助金额:
    $ 14.91万
  • 项目类别:
DEVELOPMENT OF CARBOXYFULLERENE DRUGS TO TREAT ALS
治疗 ALS 的羧基富勒烯药物的开发
  • 批准号:
    2715542
  • 财政年份:
    1998
  • 资助金额:
    $ 14.91万
  • 项目类别:
CARBON ENCAPSULATED RADIONUCLIDE CHELATES
碳封装放射性核素螯合物
  • 批准号:
    2011272
  • 财政年份:
    1997
  • 资助金额:
    $ 14.91万
  • 项目类别:
GADOLINIUM CONTAINING FULLERENES AS MRI CONTRAST AGENTS
含钆富勒烯作为 MRI 造影剂
  • 批准号:
    2776395
  • 财政年份:
    1996
  • 资助金额:
    $ 14.91万
  • 项目类别:
GADOLINIUM CONTAINING FULLERENES AS MRI CONTRAST AGENTS
含钆富勒烯作为 MRI 造影剂
  • 批准号:
    6172257
  • 财政年份:
    1996
  • 资助金额:
    $ 14.91万
  • 项目类别:
GADOLINIUM CONTAINING FULLERENES AS MRI CONTRAST AGENTS
含钆富勒烯作为 MRI 造影剂
  • 批准号:
    2109715
  • 财政年份:
    1996
  • 资助金额:
    $ 14.91万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了